anxiety and glp-1 The risk of depression, anxiety, suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy The risk of depression, anxiety,

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression

If GLP-1s do what the evidence suggests they will do, this will be one of the clearest demonstrations in modern psychiatry of why we fund preclinical research and why translational pipelines matter

The Protein-Muscle Problem Research shows that up to 20 to 25 percent of weight lost on GLP-1 medications can come from muscle rather than fat

New data from 333,000 patients: 3 years on: 18% risk of heart attack, stroke, death Stop at 12 months: +14% risk Stop at 18 months: benefit fully erased Stop at 24 months: +22% risk It takes 3 years to build it

The result: balanced appetite cues and everyday metabolic wellness, all powered by nutritionnot drugs.*

EllieMD and Hers